FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597486205> ?p ?o ?g. }

• W2597486205 endingPage "1222" @default.
• W2597486205 startingPage "1213" @default.
• W2597486205 abstract "Essentials•MEDI2452 is a specific antidote of the platelet P2Y12 receptor antagonist ticagrelor.•Hemostatic effects of MEDI2452 were evaluated in pigs treated with ticagrelor and aspirin.•MEDI2452 eliminated free ticagrelor within 5 min and gradually normalized platelet aggregation.•Improvements in blood pressure (significant) and in blood‐loss and survival (non‐significant) were observed.Summary: BackgroundTicagrelor, a P2Y12 antagonist, is approved for the prevention of thromboembolic events. However, antiplatelet therapies carry a risk of bleeding.ObjectiveTo explore the hemostatic effects of MEDI2452, an antidote for ticagrelor.MethodsPigs, pre‐treated with aspirin, were given an intravenous infusion of ticagrelor or vehicle. At the end of the infusion, a piece of a liver lobe was cut off and a bolus of MEDI2452 or vehicle was administered intravenously. Blood was collected to monitor blood loss, mean arterial blood pressure (MAP) was recorded and survival time was observed over 4 h. Blood samples for drug plasma exposures and platelet aggregation were collected.ResultsMEDI2452 eliminated the free concentrations of ticagrelor and its active metabolite AR‐C124910XX within 5 min. ADP‐induced platelet aggregation was close to normal at 60 min, which was not significantly different from aspirin alone. MEDI2452 numerically reduced ticagrelor‐mediated effects: body‐weight‐adjusted blood loss in the 15‐ to 90‐min interval, 12 (confidence interval [CI] 95% 7–28] vs. 17 (CI 95% 5–31) (ticagrelor and aspirin) vs. 5 (CI 95% 3–9) mL kg−1 (aspirin alone), survival 70% (CI 95% 47–100) vs. 45% (CI 95% 21–92) (ticagrelor and aspirin) vs. 100% (CI 95% 100–100) (aspirin alone), and median survival time, 240 (CI 95% 180–240) vs. 169 (CI 95% 64–240) (ticagrelor and aspirin) vs. 240 (CI 95% 240–240) min (aspirin alone). Finally, MEDI2452 significantly attenuated the decline in MAP, 0.08 (CI 95% 0.07–0.09) vs. 0.141 (CI 95% 0.135–0.148) (ticagrelor and aspirin) vs. 0.04 (CI 95% 0.03–0.05) mmHg per min (aspirin alone) and maintained MAP at a significantly higher level, 73 (CI 95% 51–95) vs. 48 (CI 95% 25–70) (ticagrelor and aspirin) vs. 115 (CI 95% 94–136) mmHg (aspirin alone).ConclusionMEDI2452 eliminated free ticagrelor and AR‐C124910XX within 5 min. This translated into a gradual normalization of ADP‐induced platelet aggregation and significant improvement in blood pressure and numerical but non‐significant improvements in blood‐loss and survival. Essentials•MEDI2452 is a specific antidote of the platelet P2Y12 receptor antagonist ticagrelor.•Hemostatic effects of MEDI2452 were evaluated in pigs treated with ticagrelor and aspirin.•MEDI2452 eliminated free ticagrelor within 5 min and gradually normalized platelet aggregation.•Improvements in blood pressure (significant) and in blood‐loss and survival (non‐significant) were observed. •MEDI2452 is a specific antidote of the platelet P2Y12 receptor antagonist ticagrelor.•Hemostatic effects of MEDI2452 were evaluated in pigs treated with ticagrelor and aspirin.•MEDI2452 eliminated free ticagrelor within 5 min and gradually normalized platelet aggregation.•Improvements in blood pressure (significant) and in blood‐loss and survival (non‐significant) were observed. Ticagrelor, a P2Y12 antagonist, is approved for the prevention of thromboembolic events. However, antiplatelet therapies carry a risk of bleeding. To explore the hemostatic effects of MEDI2452, an antidote for ticagrelor. Pigs, pre‐treated with aspirin, were given an intravenous infusion of ticagrelor or vehicle. At the end of the infusion, a piece of a liver lobe was cut off and a bolus of MEDI2452 or vehicle was administered intravenously. Blood was collected to monitor blood loss, mean arterial blood pressure (MAP) was recorded and survival time was observed over 4 h. Blood samples for drug plasma exposures and platelet aggregation were collected. MEDI2452 eliminated the free concentrations of ticagrelor and its active metabolite AR‐C124910XX within 5 min. ADP‐induced platelet aggregation was close to normal at 60 min, which was not significantly different from aspirin alone. MEDI2452 numerically reduced ticagrelor‐mediated effects: body‐weight‐adjusted blood loss in the 15‐ to 90‐min interval, 12 (confidence interval [CI] 95% 7–28] vs. 17 (CI 95% 5–31) (ticagrelor and aspirin) vs. 5 (CI 95% 3–9) mL kg−1 (aspirin alone), survival 70% (CI 95% 47–100) vs. 45% (CI 95% 21–92) (ticagrelor and aspirin) vs. 100% (CI 95% 100–100) (aspirin alone), and median survival time, 240 (CI 95% 180–240) vs. 169 (CI 95% 64–240) (ticagrelor and aspirin) vs. 240 (CI 95% 240–240) min (aspirin alone). Finally, MEDI2452 significantly attenuated the decline in MAP, 0.08 (CI 95% 0.07–0.09) vs. 0.141 (CI 95% 0.135–0.148) (ticagrelor and aspirin) vs. 0.04 (CI 95% 0.03–0.05) mmHg per min (aspirin alone) and maintained MAP at a significantly higher level, 73 (CI 95% 51–95) vs. 48 (CI 95% 25–70) (ticagrelor and aspirin) vs. 115 (CI 95% 94–136) mmHg (aspirin alone). MEDI2452 eliminated free ticagrelor and AR‐C124910XX within 5 min. This translated into a gradual normalization of ADP‐induced platelet aggregation and significant improvement in blood pressure and numerical but non‐significant improvements in blood‐loss and survival." @default.
• W2597486205 created "2017-04-07" @default.
• W2597486205 creator A5002506738 @default.
• W2597486205 creator A5008926411 @default.
• W2597486205 creator A5010956157 @default.
• W2597486205 creator A5033265462 @default.
• W2597486205 creator A5058176848 @default.
• W2597486205 creator A5058949331 @default.
• W2597486205 creator A5066158458 @default.
• W2597486205 creator A5070973655 @default.
• W2597486205 creator A5079646068 @default.
• W2597486205 creator A5083813412 @default.
• W2597486205 date "2017-06-01" @default.
• W2597486205 modified "2023-09-30" @default.
• W2597486205 title "Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin" @default.
• W2597486205 cites W136622145 @default.
• W2597486205 cites W1965140275 @default.
• W2597486205 cites W1996554118 @default.
• W2597486205 cites W2007373968 @default.
• W2597486205 cites W2007957848 @default.
• W2597486205 cites W2027911210 @default.
• W2597486205 cites W2060258953 @default.
• W2597486205 cites W2063213732 @default.
• W2597486205 cites W2078541011 @default.
• W2597486205 cites W2109514366 @default.
• W2597486205 cites W2131181128 @default.
• W2597486205 cites W2140501627 @default.
• W2597486205 cites W2141358924 @default.
• W2597486205 cites W2151434250 @default.
• W2597486205 cites W2153443504 @default.
• W2597486205 cites W2156255513 @default.
• W2597486205 cites W2160678403 @default.
• W2597486205 cites W2234936278 @default.
• W2597486205 cites W2359884680 @default.
• W2597486205 cites W2443293408 @default.
• W2597486205 cites W2522187540 @default.
• W2597486205 cites W4229673533 @default.
• W2597486205 doi "https://doi.org/10.1111/jth.13680" @default.
• W2597486205 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28322016" @default.
• W2597486205 hasPublicationYear "2017" @default.
• W2597486205 type Work @default.
• W2597486205 sameAs 2597486205 @default.
• W2597486205 citedByCount "20" @default.
• W2597486205 countsByYear W25974862052017 @default.
• W2597486205 countsByYear W25974862052018 @default.
• W2597486205 countsByYear W25974862052019 @default.
• W2597486205 countsByYear W25974862052020 @default.
• W2597486205 countsByYear W25974862052021 @default.
• W2597486205 countsByYear W25974862052022 @default.
• W2597486205 countsByYear W25974862052023 @default.
• W2597486205 crossrefType "journal-article" @default.
• W2597486205 hasAuthorship W2597486205A5002506738 @default.
• W2597486205 hasAuthorship W2597486205A5008926411 @default.
• W2597486205 hasAuthorship W2597486205A5010956157 @default.
• W2597486205 hasAuthorship W2597486205A5033265462 @default.
• W2597486205 hasAuthorship W2597486205A5058176848 @default.
• W2597486205 hasAuthorship W2597486205A5058949331 @default.
• W2597486205 hasAuthorship W2597486205A5066158458 @default.
• W2597486205 hasAuthorship W2597486205A5070973655 @default.
• W2597486205 hasAuthorship W2597486205A5079646068 @default.
• W2597486205 hasAuthorship W2597486205A5083813412 @default.
• W2597486205 hasBestOaLocation W25974862051 @default.
• W2597486205 hasConcept C126322002 @default.
• W2597486205 hasConcept C1621761 @default.
• W2597486205 hasConcept C2777628954 @default.
• W2597486205 hasConcept C2777849778 @default.
• W2597486205 hasConcept C2779365888 @default.
• W2597486205 hasConcept C2780890252 @default.
• W2597486205 hasConcept C29730261 @default.
• W2597486205 hasConcept C42219234 @default.
• W2597486205 hasConcept C43376680 @default.
• W2597486205 hasConcept C49059817 @default.
• W2597486205 hasConcept C71924100 @default.
• W2597486205 hasConcept C89560881 @default.
• W2597486205 hasConcept C98274493 @default.
• W2597486205 hasConceptScore W2597486205C126322002 @default.
• W2597486205 hasConceptScore W2597486205C1621761 @default.
• W2597486205 hasConceptScore W2597486205C2777628954 @default.
• W2597486205 hasConceptScore W2597486205C2777849778 @default.
• W2597486205 hasConceptScore W2597486205C2779365888 @default.
• W2597486205 hasConceptScore W2597486205C2780890252 @default.
• W2597486205 hasConceptScore W2597486205C29730261 @default.
• W2597486205 hasConceptScore W2597486205C42219234 @default.
• W2597486205 hasConceptScore W2597486205C43376680 @default.
• W2597486205 hasConceptScore W2597486205C49059817 @default.
• W2597486205 hasConceptScore W2597486205C71924100 @default.
• W2597486205 hasConceptScore W2597486205C89560881 @default.
• W2597486205 hasConceptScore W2597486205C98274493 @default.
• W2597486205 hasFunder F4320307770 @default.
• W2597486205 hasFunder F4320322783 @default.
• W2597486205 hasIssue "6" @default.
• W2597486205 hasLocation W25974862051 @default.
• W2597486205 hasLocation W25974862052 @default.
• W2597486205 hasOpenAccess W2597486205 @default.
• W2597486205 hasPrimaryLocation W25974862051 @default.
• W2597486205 hasRelatedWork W1982513890 @default.
• W2597486205 hasRelatedWork W2094353400 @default.
• W2597486205 hasRelatedWork W2318219273 @default.

• next